# Real-World Study of Ceftazidime Avibactam in China

> **NCT05487586** · — · TERMINATED · sponsor: **Pfizer** · enrollment: 220 (actual)

## Conditions studied

- Hospital Acquired Pneumonia
- Ventilator Acquired Pneumonia
- Complicated Intra Abdominal Infections

## Interventions

- **DRUG:** ceftazidime avibactam group

## Key facts

- **NCT ID:** NCT05487586
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-20
- **Primary completion:** 2024-07-11
- **Final completion:** 2024-07-11
- **Target enrollment:** 220 (ACTUAL)
- **Why stopped:** The study was prematurely discontinued due to slow enrollment and strategic considerations. This decision was not based on any safety or efficacy concerns.
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05487586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05487586, "Real-World Study of Ceftazidime Avibactam in China". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05487586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*